WO2015020240A1 - 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물 - Google Patents
엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물 Download PDFInfo
- Publication number
- WO2015020240A1 WO2015020240A1 PCT/KR2013/007085 KR2013007085W WO2015020240A1 WO 2015020240 A1 WO2015020240 A1 WO 2015020240A1 KR 2013007085 W KR2013007085 W KR 2013007085W WO 2015020240 A1 WO2015020240 A1 WO 2015020240A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- entecavir
- microspheres
- biocompatible polymer
- polyglycolide
- biodegradable biocompatible
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Definitions
- Sustained release injectable formulations refer to injectable formulations which are formulated so that the drug can be continuously and uniformly released while maintaining biological activity in the body during subcutaneous or intramuscular injection.
- the aliphatic polyester developed and used as a polymer carrier in such a depot formulation has already been approved by the US Food and Drug Administration (FDA) for its biocompatibility, and is widely used for drug delivery carriers or surgical sutures. .
- FDA US Food and Drug Administration
- aliphatic polyesters include poly-L-lactic acid, polyglycolic acid, poly-D-lactic acid-co-glycolic acid, poly-L-lactic acid-co-glycolic acid, poly-D, L-lactic acid-co- Glycolic acid (hereinafter referred to as 'PLGA'), poly-caprolactone, poly-valerolactone, poly-hydroxy butyrate and poly-hydroxy valerate, and the like [Peppas, LB, Int. J. Pharm. , 116, 1-9, 1995].
- a depot formulation is prepared by using a phase separation method.
- a silicone oil, heptene, ethyl alcohol, etc. must be used together with a methylene chloride solvent, and all organic solvents must be removed. It has the disadvantage of being complicated.
- U.S. Patent No. 5366734 discloses a sustained release drug-release preparation in the form of an implant incorporating a drug in a biodegradable polymer, but has a disadvantage in that the injection needle of the syringe becomes large due to the size of the implant itself, thereby decreasing patient compliance with the patient.
- Korean Patent Laid-Open Publication No. 2002-0011975 also discloses a method for preparing microspheres by using a solvent extraction method, but this method also has a disadvantage in that a large amount of solvent exists in the microspheres after washing even if the solvent has a high boiling point. .
- U.S. Patent No. 44652441 forms microspheres by forming a three-phase emulsion containing the active ingredient and then encapsulating the active ingredient in a polymer by an underwater drying method.
- the water-soluble active ingredient is exposed to an external aqueous phase to decrease its encapsulation rate. Therefore, there is a problem that it is difficult to obtain microspheres having a high content of the drug.
- Korean Patent No. 0994658 discloses a method for preparing a water-soluble peptide drug by a multi-emulsion method of solvent volatilization, but this method is applicable only to an active ingredient having high water solubility and difficult to apply to an active ingredient having low solubility. .
- drugs that have been developed as sustained-release injections include drugs that must be administered daily as injections (GNRH drugs: tryptorelin, leuprolide, goserelin, etc.) and psychosocial drugs (risperidone, olanzapine, paliperidone, naltrexone).
- GNRH-type drugs can be administered for a period of time in order to alleviate the discomfort that patients must receive daily injections, and in the case of psychosocial drugs, the patient is reluctant to take the drug itself.
- Formulations have been required at the clinical site and have thus been developed as sustained release injections. In other words, it is not necessary to develop oral preparations as injectables, except in special cases such as mental nervous system drugs. Since entecavir was developed as an easy to administer oral solution, there was no need to develop them as injections. Since sustained-release development was not easy to think of, until now, entecavir has been administered only as an oral preparation.
- the conventional method for preparing microspheres is usually prepared by dissolving the main component and the polymer using methylene chloride, benzyl alcohol, ethyl acetate, etc. as an organic phase and putting them in a continuous phase of the aqueous phase to produce microspheres. It is difficult to manufacture the microspheres because the solubility is not high.
- the concept of developing sustained-release injections is not easy to develop, and to develop enticavir, which is technically difficult to produce microspheres, as a sustained-release injection, it was intended to improve the compliance with medicines.
- a solvent having a sufficiently high solubility in entecavir was selected, and earnest research was conducted to achieve the present invention.
- the present invention aims to improve the compliance of the entercavir which has been administered only for oral use, and to prepare the entercavir as microparticles of biodegradable biocompatible polymer to provide a sustained-release parenteral preparation.
- the present invention provides entecavir microspheres composed of a biodegradable biocompatible polymer containing entecavir or a pharmaceutically acceptable salt thereof.
- Biodegradable biocompatible polymers in the present invention are selected from poly (lactide-co-glycolide), polylactide, polyglycolide, poly (lactide-co-glycolide) glucose, polycaprolactone, gelatin and hyaluronate.
- Polyglycolide, polylactide and polyglycolide with polylactide copolymers and the like are preferred.
- the molar ratio of lactide to glycolide is preferably from 50:50 to 90:10.
- biodegradable biocompatible polymers used in the present invention may have an intrinsic viscosity of 0.1 to 1.9 dl / g, and it is preferable to use at least one polymer having an intrinsic viscosity of 0.3 to 1.9 dl / g.
- the entecavir microspheres according to the invention may contain from 1 to 90% by weight of entecavir, preferably from 10 to 60% by weight of entecavir.
- the size of the entercavir microspheres may be 1 to 250 ⁇ m, preferably 10 to 200 ⁇ m.
- the entecavir microspheres prepared in accordance with the present invention are sustained release and can sustain release for at least 30 days.
- a method of preparing a dispersion phase was prepared by dissolving enticavir in a solvent in which well dissolved, followed by mixing with a solution in which a polymer was dissolved.
- the encapsulation rate was low, whereas the encapsulation rate was excellent according to the method of the present invention.
- Solvents usable for dissolving enticavir in the present invention include dimethylsulfoxide, dimethylformamide, acetic acid, hydrochloric acid, methanol, ethanol and water for injection, in particular dimethylsulfoxide, dimethylformamide or acetic acid Acidic solutions, such as hydrochloric acid, are preferable.
- a polymer such as polyvinyl alcohol, polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, and the like may be used as the hydrophilic polymer aqueous solution for preparing microspheres by adding a dispersion solution of entecavir and a polymer solution.
- the removal of the organic solvent can be carried out by applying any solvent removal method commonly used, for example, stirring, heating, nitrogen purge (N 2 purge) and the like.
- the pharmaceutical composition comprising entecavir microspheres according to the present invention can be used as a therapeutic agent for chronic hepatitis B virus infection, the dosage can be variously adjusted according to the age, symptoms, dosage form of the patient, and 0.1 to 5.0 mg as entecavir / day, preferably 0.2 to 3.0 mg / day, more preferably 0.5 to 1.0 mg / day.
- the pharmaceutical composition according to the present invention may be prepared using a pharmaceutically acceptable conventional carrier, and may use a conventional manufacturing method to achieve high bioavailability.
- the entecavir microspheres of the present invention may be provided as a formulation administered in suspension in an injectable suspension upon final administration.
- Injectable suspensions may be, for example, water-soluble organic carriers, for example, isotonic agents, thickeners, surfactants, buffers, and the like.
- Usable isotonic agents can be water-soluble excipients or sugars such as mannitol, sucrose, sorbitol, trehalose, lactose and the like, and examples of the thickener include carmellose sodium, carboxymethylcellulose sodium, povidone and the like.
- polysorbate 80, polysorbate 20, and the like may be used as the polyoxyethylene sorbitan, and span 80 and span 20 may be used as the sorbitan ester.
- the buffer sodium monohydrogen phosphate, citric anhydride, sodium hydroxide, sodium chloride and the like can be used.
- the entecavir microspheres prepared according to the present invention have an average of 80% or more of the entecavir input and are sufficiently contained in the microspheres and are eluted for at least 30 days. This can improve patient compliance.
- FIG. 1 is a SEM photograph of the microspheres prepared in the preparation example and the comparative example
- Figure 1a is a microsphere of Example 6
- Figure 1b is a microsphere of the comparative example.
- Figure 2 shows the particle size distribution of the microspheres prepared in Example 4.
- Figure 5 is a micrograph of the injection site in rats 4 weeks after subcutaneous administration of entecavir and excipients
- Figure 5a is a group of entecavir 2.33 mg / kg / day administration
- Figure 5b is an excipient administration group.
- microspheres were washed several times with water for injection and then lyophilized to prepare microspheres.
- Biodegradable polymers used in this example are shown in Table 1 below.
- the polymers used in the above examples are all copolymers, RG means polylactide glycolide copolymer, H means that the end of the polymer is hydrophilic (hydrophilic endgroup), S means that the hydrophobic endgroup.
- the first two digits in the middle number refer to the ratio of lactide in the copolymer, for example, 50 means a copolymer having 50% lactide, and 75 means a copolymer having 75% lactide. And the last digit shows the difference between the polymer grade and the intrinsic viscosity, for example, 502H is 0.16 to 0.24 dl / g, 504H is 0.45 to 0.60 dl / g.
- An aqueous phase was prepared by mixing 90.61 g 1% polyvinyl alcohol, 2.97 g benzyl alcohol and 6.53 g ethyl acetate. Then, 2.93 g of biodegradable polymer RG757S is dissolved in 10.87 g of ethyl acetate and 10.84 g of benzyl alcohol. When the polymer is completely dissolved, 1.57 g of enticavir is added to form an organic solvent. Microspheres were formed using an L4RT mixer (Silverson, UK) at 3000 rpm while injecting the prepared organic solvent phase.
- Figure 2 shows the particle size distribution of the microspheres prepared in Example 4.
- 3 and 4 are graphs showing the dissolution rate (%) with time in-vitro long - term dissolution test results of the microspheres prepared in Examples and Comparative Examples.
- the entecavir microspheres prepared according to the present invention can be controlled for more than 30 days drug release by changing the type of biodegradable biocompatible polymer.
- Excipients were treated with entecavir 2.33 mg / kg / day subcutaneously in 15 rats per male group, and at 1,4, 5, 8 and 12 weeks of mortality, general symptoms, body weight, autopsy findings and histopathological examination. Compared with.
- FIG. 5 is a micrograph (H & E staining, 100-fold) of the injection site in rats 4 weeks after subcutaneous administration of entecavir and excipients
- FIG. 5A is a group of entecavir 2.33 mg / kg / day
- FIG. 5B is a group of excipients.
- FIG. 5A microscopic subcutaneous inflammatory cells were observed at the injection site, but this was not significant at the excipient injection site of FIG. 5B.
- Diluent preparation 230 mg of sodium carmellose, 10 mg of polysorbate20, 10 mg of sodium monohydrogen phosphate, and 60 mg of sodium chloride were dissolved in purified water for injection to make 10 mL, and sodium hydroxide was added to prepare pH 7.0.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (16)
- 엔테카비어 또는 그의 약제학적으로 허용되는 염을 포함하는 생분해성 생체적합성 고분자로 이루어진 엔테카비어 미립구.
- 제 1 항에 있어서, 상기 생분해성 생체적합성 고분자는 폴리(락타이드-코-글리콜라이드), 폴리락타이드, 폴리글리콜라이드, 폴리(락타이드-코-글리콜라이드)글루코즈, 폴리카프로락톤, 젤라틴 및 히알우로네이트 중의 하나 이상인 것을 특징으로 하는 엔테카비어 미립구.
- 제 2 항에 있어서, 상기 생분해성 생체적합성 고분자가 폴리글리콜라이드, 폴리락타이드 및 폴리글리콜라이드와 폴리락타이드 공중합체 중의 하나 이상인 것을 특징으로 하는 엔테카비어 미립구.
- 제 3 항에 있어서, 상기 폴리글리콜라이드와 폴리락타이드 공중합체는 락타이드 대 글라이콜라이드의 몰비가 50:50 내지 90:10인 것을 특징으로 하는 엔테카비어 미립구.
- 제 1 항에 있어서, 10 내지 60 중량%의 엔테카비어를 함유하는 것을 특징으로 하는 엔테카비어 미립구.
- 제 1 항에 있어서, 크기가 10 내지 200 ㎛인 것을 특징으로 하는 엔테카비어 미립구.
- 제 1 항에 있어서, 엔테카비어 방출이 30일 이상 지속되는 것을 특징으로 하는 엔테카비어 미립구.
- 엔테카비어 및 1 종 이상의 생분해성 생체적합성 고분자를 1종 이상의 용매에 용해시키는 단계;상기 엔테카비어 및 생분해성 생체적합성 고분자의 용액을 친수성 고분자 수용액에 넣고 교반하여 미립구를 형성시키는 단계; 및용매를 제거하는 단계를 포함하는 엔테카비어 미립구의 제조방법.
- 제 8 항에 있어서, 상기 생분해성 생체적합성 고분자는 고유점도가 0.1 내지 1.9 dL/g인 것을 특징으로 하는 제조방법.
- 제 8 항에 있어서, 상기 생분해성 생체적합성 고분자는 폴리(락타이드-코-글리콜라이드), 폴리락타이드, 폴리글리콜라이드, 폴리(락타이드-코-글리콜라이드)글루코즈, 폴리카프로락톤, 젤라틴 및 히알우로네이트 중의 하나 이상인 것을 특징으로 하는 제조방법.
- 제 10 항에 있어서, 상기 생분해성 생체적합성 고분자가 폴리글리콜라이드, 폴리락타이드 및 폴리글리콜라이드와 폴리락타이드 공중합체 중의 하나 이상인 것을 특징으로 하는 제조방법.
- 제 11 항에 있어서, 상기 폴리글리콜라이드와 폴리락타이드 공중합체는 락타이드 대 글라이콜라이드의 몰비가 50:50 내지 90:10인 것을 특징으로 하는 제조방법.
- 제 8 항에 있어서, 엔테카비어를 용해시키는 용매가 다이메틸설폭사이드, 다이메틸포름아미드, 아세트산, 염산, 메탄올, 에탄올 및 주사용수 중의 하나 이상인 것을 특징으로 하는 제조방법.
- 제 13 항에 있어서, 상기 용매가 다이메틸설폭사이드, 다이메틸포름아미드, 아세트산 및 염산 중의 하나 이상인 것을 특징으로 하는 제조방법.
- 제 1 항에 따른 엔테카비어 미립구 및 약제학적 담체를 포함하는 비경구투여용 약제학적 조성물.
- 제 15 항에 있어서, 주사제용 약제학적 조성물.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2016001607A MX2016001607A (es) | 2013-08-06 | 2013-08-06 | Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas. |
CN201380078718.6A CN105722503A (zh) | 2013-08-06 | 2013-08-06 | 恩替卡韦微球及包含其的非口服给药用药学组合物 |
JP2016532997A JP2016527308A (ja) | 2013-08-06 | 2013-08-06 | エンテカビル微小球及びこれを含む非経口投与用医薬組成物 |
RU2016107827A RU2016107827A (ru) | 2013-08-06 | 2013-08-06 | Микросферы энтекавира и фармацевтическая композиция для парентерального введения, содержащая их |
PCT/KR2013/007085 WO2015020240A1 (ko) | 2013-08-06 | 2013-08-06 | 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물 |
BR112016002342A BR112016002342A8 (pt) | 2013-08-06 | 2013-08-06 | microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica |
US14/910,570 US20160175313A1 (en) | 2013-08-06 | 2013-08-06 | Entecavir microspheres and pharmaceutical composition for parenteral administration containing same |
EP13891194.6A EP3031449A4 (en) | 2013-08-06 | 2013-08-06 | Entecavir microspheres and pharmaceutical composition for parenteral administration containing same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2013/007085 WO2015020240A1 (ko) | 2013-08-06 | 2013-08-06 | 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015020240A1 true WO2015020240A1 (ko) | 2015-02-12 |
Family
ID=52461556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/007085 WO2015020240A1 (ko) | 2013-08-06 | 2013-08-06 | 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20160175313A1 (ko) |
EP (1) | EP3031449A4 (ko) |
JP (1) | JP2016527308A (ko) |
CN (1) | CN105722503A (ko) |
BR (1) | BR112016002342A8 (ko) |
MX (1) | MX2016001607A (ko) |
RU (1) | RU2016107827A (ko) |
WO (1) | WO2015020240A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017068245A1 (en) | 2015-10-22 | 2017-04-27 | Delsitech Oy | Hydrogel composite depot formulation |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102047983B1 (ko) | 2017-11-30 | 2019-11-22 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
CN108586722B (zh) * | 2018-03-01 | 2019-09-17 | 苏州大学 | 末端含硫辛酰基的星型聚合物、其制备方法及由其制备的聚合物纳米粒子与应用 |
CN108938572B (zh) * | 2018-09-27 | 2021-04-20 | 烟台大学 | 一种含有恩替卡韦的长效注射微球及其制备方法 |
CN113081952A (zh) * | 2021-04-12 | 2021-07-09 | 山东谷雨春生物科技有限公司 | 一种含有恩替卡韦的长效注射凝胶 |
KR20230036886A (ko) * | 2021-09-08 | 2023-03-15 | 주식회사 아울바이오 | 생분해성 고분자를 이용한 서방형 미립구 및 이의 제조방법 |
CN116650497A (zh) * | 2022-09-30 | 2023-08-29 | 广州帝奇医药技术有限公司 | 一种抗病毒药物组合物及其制备工艺与应用 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4652441A (en) | 1983-11-04 | 1987-03-24 | Takeda Chemical Industries, Ltd. | Prolonged release microcapsule and its production |
US4673595A (en) | 1984-10-17 | 1987-06-16 | Debiopharm, S.A. | Microencapsulation by phase separation of water-soluble medicaments |
US5366734A (en) | 1981-02-16 | 1994-11-22 | Zeneca Limited | Continuous release pharmaceutical compositions |
KR20020011975A (ko) | 1999-04-09 | 2002-02-09 | 폴. 제이. 샤벨 | 주사용 날트렉손 마이크로스피어 조성물 및 헤로인 및알코올 소비를 감소시키기 위한 이것의 용도 |
KR100354270B1 (ko) | 1993-11-19 | 2003-02-11 | 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii | 마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸 |
KR100432677B1 (ko) | 1996-05-07 | 2004-09-13 | 얀센 파마슈티카 엔.브이. | 미립자 |
KR20040099403A (ko) * | 2002-04-08 | 2004-11-26 | 브리스톨-마이어스 스큅 컴퍼니 | 저 투여량의 액체 엔테카비르 제제 및 용도 |
KR100537713B1 (ko) | 1997-09-30 | 2005-12-20 | 일라이 릴리 앤드 캄파니 | 2-메틸-티에노-벤조디아제핀 제제 |
KR100566573B1 (ko) | 2002-04-13 | 2006-03-31 | 주식회사 펩트론 | Lhrh 동족체를 함유하는 서방성 미립구의 제조방법 |
KR100994658B1 (ko) | 2001-12-26 | 2010-11-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 신규 마이크로스피어 및 이들의 제조 방법 |
KR20110026311A (ko) * | 2009-09-07 | 2011-03-15 | 제일약품주식회사 | 엔테카비어의 신규한 염 |
CN102058521A (zh) * | 2009-11-17 | 2011-05-18 | 天津天成制药有限公司 | 一种含活性成分恩替卡韦经注射给药的制剂 |
KR20120138908A (ko) * | 2011-06-16 | 2012-12-27 | 건일제약 주식회사 | 엔테카비르를 함유하는 미립구 및 이의 제조방법 |
KR101285008B1 (ko) * | 2012-04-18 | 2013-07-10 | 제일약품주식회사 | 저용량 엔테카비어의 경구투여 제제의 제조방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002506876A (ja) * | 1998-03-18 | 2002-03-05 | ユニバーシティ テクノロジー コーポレーション | 非晶質ポリマーを含む持続放出性組成物 |
KR100321854B1 (ko) * | 1998-12-30 | 2002-08-28 | 동국제약 주식회사 | 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법 |
KR100816065B1 (ko) * | 2006-11-27 | 2008-03-24 | 동국제약 주식회사 | 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐 |
US20110206773A1 (en) * | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
KR100963435B1 (ko) * | 2008-06-19 | 2010-06-17 | 한국과학기술연구원 | 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법 |
KR101113044B1 (ko) * | 2008-08-29 | 2012-02-27 | 동국제약 주식회사 | 용매교류증발법에 의한 서방출성 미립구의 제조방법 |
JP2013053103A (ja) * | 2011-09-05 | 2013-03-21 | Ltt Bio-Pharma Co Ltd | 薬物を封入した肝臓集積性ナノ粒子 |
CN102908312B (zh) * | 2011-11-10 | 2014-06-04 | 陈小花 | 抗乙肝病毒液体组合物 |
TWI568453B (zh) * | 2011-11-22 | 2017-02-01 | 原創生醫股份有限公司 | 具有螯合型複合微胞之藥物載體及其應用 |
-
2013
- 2013-08-06 CN CN201380078718.6A patent/CN105722503A/zh active Pending
- 2013-08-06 MX MX2016001607A patent/MX2016001607A/es unknown
- 2013-08-06 BR BR112016002342A patent/BR112016002342A8/pt not_active IP Right Cessation
- 2013-08-06 EP EP13891194.6A patent/EP3031449A4/en not_active Withdrawn
- 2013-08-06 RU RU2016107827A patent/RU2016107827A/ru unknown
- 2013-08-06 JP JP2016532997A patent/JP2016527308A/ja active Pending
- 2013-08-06 WO PCT/KR2013/007085 patent/WO2015020240A1/ko active Application Filing
- 2013-08-06 US US14/910,570 patent/US20160175313A1/en not_active Abandoned
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5366734A (en) | 1981-02-16 | 1994-11-22 | Zeneca Limited | Continuous release pharmaceutical compositions |
US4652441A (en) | 1983-11-04 | 1987-03-24 | Takeda Chemical Industries, Ltd. | Prolonged release microcapsule and its production |
US4673595A (en) | 1984-10-17 | 1987-06-16 | Debiopharm, S.A. | Microencapsulation by phase separation of water-soluble medicaments |
KR100354270B1 (ko) | 1993-11-19 | 2003-02-11 | 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii | 마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸 |
KR100432677B1 (ko) | 1996-05-07 | 2004-09-13 | 얀센 파마슈티카 엔.브이. | 미립자 |
KR100537713B1 (ko) | 1997-09-30 | 2005-12-20 | 일라이 릴리 앤드 캄파니 | 2-메틸-티에노-벤조디아제핀 제제 |
KR20020011975A (ko) | 1999-04-09 | 2002-02-09 | 폴. 제이. 샤벨 | 주사용 날트렉손 마이크로스피어 조성물 및 헤로인 및알코올 소비를 감소시키기 위한 이것의 용도 |
KR100994658B1 (ko) | 2001-12-26 | 2010-11-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 신규 마이크로스피어 및 이들의 제조 방법 |
KR20040099403A (ko) * | 2002-04-08 | 2004-11-26 | 브리스톨-마이어스 스큅 컴퍼니 | 저 투여량의 액체 엔테카비르 제제 및 용도 |
KR100566573B1 (ko) | 2002-04-13 | 2006-03-31 | 주식회사 펩트론 | Lhrh 동족체를 함유하는 서방성 미립구의 제조방법 |
KR20110026311A (ko) * | 2009-09-07 | 2011-03-15 | 제일약품주식회사 | 엔테카비어의 신규한 염 |
CN102058521A (zh) * | 2009-11-17 | 2011-05-18 | 天津天成制药有限公司 | 一种含活性成分恩替卡韦经注射给药的制剂 |
KR20120138908A (ko) * | 2011-06-16 | 2012-12-27 | 건일제약 주식회사 | 엔테카비르를 함유하는 미립구 및 이의 제조방법 |
KR101285008B1 (ko) * | 2012-04-18 | 2013-07-10 | 제일약품주식회사 | 저용량 엔테카비어의 경구투여 제제의 제조방법 |
Non-Patent Citations (2)
Title |
---|
PEPPAS, L. B., INT. J. PHARM., vol. 116, 1995, pages 1 - 9 |
See also references of EP3031449A4 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017068245A1 (en) | 2015-10-22 | 2017-04-27 | Delsitech Oy | Hydrogel composite depot formulation |
KR20180071253A (ko) * | 2015-10-22 | 2018-06-27 | 델시테크 오와이 | 하이드로겔 복합체 데포 제형 |
US10172792B2 (en) | 2015-10-22 | 2019-01-08 | Delsitech Oy | Hydrogel composite depot formulation |
AU2016342470B2 (en) * | 2015-10-22 | 2019-03-21 | Delsitech Oy | Hydrogel composite depot formulation |
KR102228986B1 (ko) | 2015-10-22 | 2021-03-18 | 델시테크 오와이 | 하이드로겔 복합체 데포 제형 |
Also Published As
Publication number | Publication date |
---|---|
RU2016107827A (ru) | 2017-09-14 |
US20160175313A1 (en) | 2016-06-23 |
CN105722503A (zh) | 2016-06-29 |
BR112016002342A2 (pt) | 2017-08-29 |
BR112016002342A8 (pt) | 2018-01-23 |
MX2016001607A (es) | 2016-06-06 |
EP3031449A4 (en) | 2017-05-10 |
EP3031449A1 (en) | 2016-06-15 |
JP2016527308A (ja) | 2016-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015020240A1 (ko) | 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물 | |
WO2014163400A1 (ko) | 도네페질을 포함하는 비경구투여용 약제학적 조성물 | |
WO2010024615A2 (ko) | 용매교류증발법에 의한 서방출성 미립구의 제조방법 | |
CN103338752B (zh) | 利培酮缓释微球组合物 | |
CN101467959B (zh) | 持续释放组合物及其制备方法 | |
WO2018221884A1 (ko) | 방출제어가 용이한 서방성 약물 미립자의 제조방법 | |
WO2021010719A1 (ko) | 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법 | |
KR20100052453A (ko) | 타달라필 함유 약제의 제조방법 | |
US20210186864A1 (en) | Sustained-release injectable composition comprising finasteride | |
KR20130100464A (ko) | 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물 | |
WO2016021835A1 (ko) | 약물 함유 서방성 미립자의 제조 방법 | |
KR101663561B1 (ko) | 서방출성 미립구의 제조방법 | |
Henry et al. | Exploration of long-acting implant formulations of hepatitis B drug entecavir | |
WO2024096554A1 (ko) | Gs-441524를 함유하는 서방출형 plga 미립구 및 이의 제조방법 | |
WO2009134091A2 (ko) | 난용성 약물을 함유하는 균일한 크기의 고분자 나노입자 제조방법 | |
KR102235011B1 (ko) | 약물 함유 plga 미립구 및 그의 제조방법 | |
CN104984327A (zh) | 一种胸腺法新缓释微球制剂及其制备方法 | |
WO2021133051A1 (ko) | 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물 | |
AU2019362730B2 (en) | Injectable long-acting naltrexone microparticle compositions | |
WO2015163689A1 (ko) | 활성 성분 (i) 함유 조성물 및 이의 제조 방법 | |
WO2023249465A1 (ko) | 엔테카비르를 포함하는 장기지속성 미립구 제제 및 이의 제조방법 | |
KR20190078017A (ko) | 도네페질을 포함하는 장기지속형 미립구 및 이의 제조방법 | |
WO2023249461A1 (ko) | 도네페질과 파모산을 함유하는 서방성 미립구 | |
WO2016195377A2 (ko) | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 | |
WO2023249464A1 (ko) | 약물과 파모산을 함유하는 서방성 미립구 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13891194 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013891194 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/001607 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2016532997 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14910570 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016002342 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2016107827 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016002342 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160202 |